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ABSTRACT 26 
Introduction: Traditionally patients with colorectal peritoneal metastases (CRPM) were offered 27 
palliative chemotherapy and best supportive care. With the introduction of cytoreductive surgery 28 
(CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), patients in the UK have been 29 
referred to nationally approved centres. This study describes the pattern of referral and outcomes of 30 
patients managed through one UK centre. 31 
Methods and Methods: A prospective register recorded referrals, demographics, prior treatment 32 
pathways, and specialist multidisciplinary team (MDT) decisions (2002-2015). Peritoneal cancer 33 
index (PCI) was recorded intra-operatively; complete cytoreduction was deemed when a CC0/1 was 34 
achieved. Complications were classified using NCI CTCAE.v.4. Median overall survivals (OS) 35 
were described for those treated by CRS/HIPEC and in derived estimates for patients with isolated 36 
peritoneal metastases treated by chemotherapy alone in the ARCAD trials consortium. 37 
Results: Two-hundred-eighty-six patients with CRPM were referred. Despite increasing numbers of 38 
referrals annually, the proportion of patients selected for CRS/HIPEC decreased from 64.5%, to 39 
40%, and to 37.1% for 2002-09, 2010-12, and 2013-15, respectively (p<0.017). CRS/HIPEC was 40 
undertaken in 117 patients with a median PCI of 7 and CC0/1 achieved in 86.3%. NCI CTCAE 41 
grade 3/4 complication rates were 9.4%; 30-day mortality was 0.85%. Median OS following 42 
CRS/HIPEC was 46.0 months: that for patients not receiving CRS/HIPEC was 13.2 months. 43 
Conclusion: The evolution of the national peritoneal treatment centre over 14 years has been 44 
associated with increased referral numbers, refinement of selection for major surgery, matched with 45 
achievements of low complication rates and survival advantages in selected patients compared with 46 
traditional non-surgical treatments. 47 
 48 
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1. Introduction 54 
The term colorectal peritoneal metastases (CRPM) is the preferred one for peritoneal 55 
carcinomatosis (PC) of colorectal origin[1]. Over the last two decades, treatment for liver 56 
metastases has become the accepted standard of care converting patients from a palliative to 57 
potentially curative path[2]. Similar approaches to peritoneal metastases are now possible and in the 58 
UK cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has been 59 
accepted as a treatment in selected patients (Table 1)[3].  60 
CRPM can present synchronously (10.3% of primary right colon cancers, 6.2% of left colon 61 
cancers, and 27% of rectal cancers) and metachronously (20% of colorectal cancers), with as many 62 
as 50% of cases demonstrating isolated disease at the time of presentation[4 9]. In the Sweden 63 
National Cancer Registry, CRPM synchronous or metachronous metastases were present in 8.3% of 64 
colorectal cancer patients and were the sole site of metastasis in 4.8% of the cases[10]. Given that in 65 
2012 more than 400,000 new colorectal cancer (CRC) cases were recorded in Europe, the burden of 66 
colorectal peritoneal disease (CRPM) has a significant impact on health services[11].  67 
Historically, the occurrence of PM originating from adenocarcinomas of non-gynecologic primary 68 
carried a poor prognosis[8,9]. Even with current systemic chemotherapy regimes, the outcome 69 
remains disappointing, with median overall and disease free survival of 30 and 10 months, 70 
respectively[12 15]. A recent editorial raised concerns at the lack of information regarding 71 
outcomes of CRPM patients undergoing systemic anticancer treatments and the lack of enrolment 72 
of this group of patients in clinical trials[16]. 73 
For CRPM, systemic chemotherapy and palliative support used to be the mainstay of treatment, 74 
with surgery restricted to relieving obstruction. In the last decade however, compelling data on 75 
outcomes following CRS/HIPEC from several specialist centres has emerged[2,17 22]. These 76 
studies have shown a median survival of 22.3 to 63 months and a 5-year survival of up to 51% is 77 
achievable with CRS/HIPEC, in a highly selected group of patients, compared to 12 to 24 months 78 
and up to 13% for matched patients receiving systemic chemotherapy alone [2,17,18,22,23]. More 79 
recently guidelines from the European Society of Medical Oncology recommend CRS/HIPEC for 80 
selected cases of CRPM[12]. 81 
Over the last decade, CRS and HIPEC for CRPM patients has been adopted by a number of groups 82 
and published series includes a randomised controlled study, a multicentre study, case series 83 
retrospective analysis, and a systematic review and meta-analysis[2,17,22,24 26]. Based on this 84 
evidence, CRS/HIPEC has been adopted for CRPM by several centers worldwide. Unfortunately, 85 
there has been little regulation regarding the introduction of CRS/HIPEC resulting in a wide 86 
variation in selection for treatment, early and late outcomes and scepticism from many in the non-87 
surgical oncological arena regarding its effectiveness. In a bid to define guidelines for treatment, a 88 
consensus was proposed and adopted by the Peritoneal Society of Oncology Group International 89 
(PSOGI) in 2015[16]. 90 
Delivery of specialist healthcare in the UK has supported the introduction of a programme of 91 
CRS/HIPEC, which has resulted in cohorts of patients being referred to national registered centres. 92 
This study aims to evaluate the trends in referral and outcomes of treatment of CRPM at one of the 93 
national peritoneal tumour centres (The Christie Hospital, Manchester). 94 
 95 
2. Methods 96 
2.1 Patients 97 
Institutional clinical audit review board approval was obtained. A prospectively collected database 98 
was used to identify patients with CRPM referred to the Colorectal and Peritoneal Oncology Centre 99 
(CPOC) at The Christie Hospital National Health Service Foundation Trust, Manchester (UK) 100 
between 2002 and June 2015. 101 
In 2013 the NHS England Commissioning Board agreed selection criteria for treatment of CRPM 102 
(Table 1). Each patient was assessed through dedicated specialist multidisciplinary team (MDT) 103 
meetings comprising of a core membership of colorectal and hepatobiliary surgeons, medical 104 
oncologists, radiologists, pathologists, and Clinical Nurse specialists all with expertise in peritoneal 105 
surface malignancy (PSM). For each case, clinical records, prior treatments, pathology review, 106 
radiologic examinations, and tumor marker measurements were recorded. The MDT allowed the 107 
complete assessment of individual cases and considered the potential treatment options concluding 108 
in a management package customised to the individual patient circumstances. For patients 109 
undergoing CRS/HIPEC the intraoperative findings, Peritoneal Cancer Index (PCI) and 110 
completeness of cytoreduction (CC) scores were recorded; PCI by definition is an intraoperative 111 
index of disease burden and hence was captured at the time of surgery in patients undergoing CRS. 112 
Although the concept of a radiological PCI at MDT is an attractive one, and has more recently been 113 
adopted in some centres this was not standard practice during the study period. Even to date there is 114 
no universally accepted and validated pre-treatment PCI scoring system. The reasons for rejecting 115 
patients for CRS/HIPEC included extent of peritoneal disease such that CC0/1 was unlikely to be 116 
achieved, active systemic disease, progressive disease on chemotherapy, and being unfit for 117 
surgery. The postoperative morbidity and mortality was recorded using the National Cancer 118 
Institute Common Terminology Criteria for Adverse Effects (NCI CTCAE), version 4.0[27]. 119 
 120 
2.2 Treatment 121 
All patients underwent general anaesthesia with central and arterial monitoring for haemodynamic, 122 
oxygenation and renal function evaluation during surgery. Wherever possible and in 90% of 123 
patients, epidural catheters were inserted to maximise postoperative pain management. 124 
CRS included visceral resection of involved organs and peritonectomy procedures as required 125 
adopted from that described by Sugarbaker[28]. Peritoneal disease burden was assessed 126 
intraoperatively using the PCI, which yields scores ranging from 0 to 39[29,30]. In all cases, the 127 
objective was to achieve a complete cytoreduction of macroscopic disease[28]. Completeness of 128 
disease removal was determined intraoperatively using the CC scoring system[31]. A score of CC0 129 
indicates no residual disease, CC1 indicates nodules less than 2.5 millimetres remaining, CC2 130 
indicates nodules between 2.5 millimetres and 2.5 centimetres remaining, and CC3 reflects nodules 131 
greater than 2.5 centimetres remaining. Where scores CC0 and CC1 were achieved, patients were 132 
classified as having a complete cytoreduction.   133 
HIPEC was delivered using a semi-closed modification of the Coliseum technique[32,33]. In the 134 
semi-closed technique, temperature probes are positioned into four quadrants to ensure equilibration 135 
of temperature during HIPEC delivery. The abdomen was filled with 2 l/m
2
 of 1.5% dextrose 136 
peritoneal dialysis solution (Dianeal, Baxter Healthcare Corporation, Deerfield, IL) prior to the 137 
introduction of 35 mg/m
2
 mitomycin C in three pulses at 30 minute intervals for a total of 90 138 
minutes at a temperature of 42°C, using the Performer® LRT system (RanD, Medolla, Italy). 139 
Alternatively, a bolus iv administration of of folinic acid (calcium folinate) 50 mg was followed by 140 
400 mg/m
2
 5-flurouracil (5FU) iv administration over an hour, which was followed by 368 mg/m
2
 141 
oxaliplatin intra-peritonealy for 30 minutes. The oxaliplatin dose was selected after reviewing the 142 
protocols of other providers at that time and decided on a reduced dose as due to possible 143 
complications without additional benefit. The use of mitomycin C or oxalipatin was determined 144 
f  e a e   c e e a  ea e  a d e a ed de effec . F  e 145 
intraperitoneal drug perfusion, the abdomen was washed with saline over 10 minutes. 146 
 147 
2.3 Postoperative Management and Follow-Up 148 
After the procedure, patients were transferred to the critical care unit (CCU), for monitoring, and 149 
support. All patients self ventilated within two hours of anaesthetic reversal. Patients remained on 150 
CCU until fluid balance, haemodynamics and pain control were deemed stable prior to transfer to 151 
the surgical ward for recovery. Patients were followed-up every 6-months for 2 years after 152 
CRS/HIPEC and annually thereafter, with CT chest/abdomen/pelvis at 6, 12, 18, 24, 36, 48, 60, and 153 
96 months accompanied by tumour markers (serum CEA, Ca125, and Ca19.9). 154 
 155 
2.4 Statistical Analysis 156 
Statistical analyses were performed using Stata® 12.0 software (College Station, TX). We 157 
described changes over time as proportions per time periods and tested for trends using chi-squared. 158 
Median overall survival was estimated using Kaplan-Meier (K-M) tables. 159 
To describe survival in patients selected to undergo CRS/HIPEC versus survival in patients with 160 
isolated peritoneal metastases treated by chemotherapy alone, we captured survival estimates from 161 
the published analysis and research in cancers of the digestive system (ARCAD) database using 162 
Engauge Digitizer, a validated software that captures published K-M curve images, and with known 163 
baseline sample sizes, derives individual-level data. From these two groups, we report median 164 
survivals but deemed it not appropriate to statistically compare[23,34]. 165 
 166 
3. Results 167 
The study consists of data from 286 patients with a confirmed CRPM diagnosis. The mean age of 168 
the study population was 57.7 years and 50.3% were males. Over time there was a significant 169 
increase in referrals/year (range: 1  80) (Figure 1). The MDT recommended against CRS/HIPEC 170 
in 169 (59.1%) patients (Figure 2) due to: extent of peritoneal disease such that CC0/1 was unlikely 171 
to be achieved (40.5%), active systemic disease (28.6%), progressive disease on chemotherapy 172 
(11.3%); and being unfit for surgery (9.5%). Seven patients refused CRS/HIPEC when offered 173 
(4.2%). 174 
There was variation over time with respect to MDT recommendations (Figure 3). During the period 175 
2002-2009, the MDT recommended CRS/HIPEC in 64.5% of CRPM referrals. This percentage 176 
decreased to 40% and 37.1% during the 2010-2012 and 2013-2015 periods, respectively. This was a 177 
statistically significant difference (p<0.017). 178 
Of the 40.9% (n=117) of patients who underwent CRS/HIPEC, there was a median PCI of 7 (range: 179 
0-31).    Forty-one (35%), 28 (24%), 32 (27%), and 11 (9%) patients had PCI range score of 0-5, 6-180 
10, 11-21, and 22-31, respectively. There were no PCI score data for 5 patients. Complete 181 
cytoreduction (CC0/1 score) was achieved in 86.3% (n=101). The mean CCU stay was 2.91 (±0.55) 182 
days and the mean hospital stay was 10.55 (±0.38) days. Combined grade 3/4 complication rate was 183 
9.4% (n=11) and the 30-day mortality rate was 0.85% (n=1). 184 
In terms of gender, age, referral region, time from CRPM diagnosis to referral, referral team / 185 
physician (i.e. surgical team, medical oncology team, general practitioner, self referral), and timing 186 
of CRPM diagnosis (i.e. before the 1st operation, at the 1st operation, later during follow-up) there 187 
were no differences between patients where CRS/HIPEC was offered and not. Equally, there were 188 
no differences in terms of pre-referral operation status and number of prior surgical interventions, 189 
pre-referral chemotherapy treatments, duration of the 1st pre-referral chemotherapy, and total 190 
duration of pre-referral chemotherapies.  191 
Pre-referral radiotherapy was offered to 2.4% of the patients that did not undergo CRS/HIPEC and 192 
to 8.6% of the patients that the MDT advised for surgery (p=0.024). 193 
Median overall survival (OS) following CRS/HIPEC was 46.0 months; for patients not undergoing 194 
CRS/HIPEC median survival was 13.2 months (Figure 4). Also included is the derived survival 195 
from the ARCAD database study. Table 2 presents the results in our study along with other 196 
equivalent non-randomised comparative studies. The OS for patients that received CRS/HIPEC had 197 
no statistically significant correlation with time from diagnosis to referral, referral period group, and 198 
referral team.  199 
 200 
4. Discussion 201 
Although there have been a number of case series addressing activity and outcomes following 202 
CRS/HIPEC for CRPM, this is among the very few studies that explore the patient pathway and 203 
describes outcomes for the complete cohort of referrals including those not undergoing surgery and 204 
those considered not suitable for CRS/HIPEC[35]. It is notable that over the period of this study, 205 
health service directives have facilitated an increase in referrals and increased awareness of 206 
CRS/HIPEC for patients with CRPM. In mainland Europe, the delivery of CRS/HIPEC varies in 207 
different countries, but in general is less regulated than in the UK. In England to date, only three 208 
providers are commissioned to offer this service for a population of 53 million. Although this has 209 
the advantage of standardising treatment in high volume centres it presents challenges of access and 210 
timely delivery of treatments for this patient group. The data from this analysis assists in identifying 211 
a a e a e  f  c de a  b  ec a  MDT  a d e  a be c a  f  de e  a 212 
quality service and achieving best outcomes for patients, restricting the provision to too few centres 213 
may limit equity of access to treatment for appropriately selected patients.  214 
This study presents the experience of a single specialist MDT and the ability to identify criteria for 215 
selection of patients for CRS/HIPEC. The increasing number of referrals could possibly reflect both 216 
the effect of the disease and the availability of the treatment becoming better known over the last 217 
five years. It is notable that overall almost 60% of patients were deemed unsuitable for CRS/HIPEC 218 
but perhaps more crucially, the percentage of the cases where the MDT advised against surgery 219 
increased from 30 to 60% over time. This is a reflection of improved discrimination by the MDT in 220 
parallel with assimilation of experience within the team and from others working in the field. For 221 
example, awareness that PCI as a key discriminator for achieving complete cytoreduction in CRPM 222 
has come to the fore over the last five years with consensus guidelines recommending an objective 223 
of complete CRS for this group of patients[16, 36 38]. In this series, a complete cytoreduction 224 
(CC0/1) was achieved in 86.3% of patients undergoing surgery. This percentage is among the 225 
highest of corresponding reported series[2,25,39,40].   226 
The achievement of high levels of cytoreduction (>86% CC0/1), low morbidity and mortality rates, 227 
reflect the strict protocols of care for pre-operative assessment, standardised intra-operative 228 
monitoring, minimal transfusion, peri-operative goal directed fluid management, early extubation 229 
with 24- to 36-hour stabilisation and epidural pain management for five postoperative days. The 230 
low morbidity and mean hospital stay of 10.5 days are among the lowest of other reported 231 
series[25,38,40,41]. The MDT selection process is focused on discriminating systemic versus 232 
peritoneal disease (median PCI of 7 in our series) and fitness for major surgery. However, it is 233 
possible that there is bias both in referral and selection that denies CRS/HIPEC treatment from a 234 
subgroup of patients who could get some clinical benefit. This study confirms that CRS/HIPEC can 235 
be performed safely with minimal postoperative mortality and acceptable morbidity when 236 
performed in the setting of an experienced centre undertaking a high volume of cases. 237 
The deficiency of this study includes the non-randomised case series, the retrospective nature, and 238 
the selection bias; however, this data provides accurate, real time information regarding outcomes 239 
for patients with CRPM. The median OS of patients selected for CRS/HIPEC was 46 months. 240 
Hence whilst potential curative cytoreduction can be achieved in some, benefits in survival can 241 
endure following CRS/ HIPEC even when complete CRS is not possible. Equally important is the 242 
data confirming median OS of 13.2 months for patients not offered CRS/HIPEC, which parallels 243 
the ARCAD[23] study and adds to our knowledge relating to current systemic anticancer treatment 244 
(SACT) for PM, an area that has been relatively neglected in the oncological literature. A recent 245 
editorial has commentated on the lack of inclusion of PM in trials of chemotherapy and inadequate 246 
data on outcomes of patients with PM as opposed to other metastatic sites from colorectal 247 
cancer[23]. The results of the PRODIGE 7 (P7) randomised trial of CRS alone versus CRS/HIPEC 248 
has yet to be published beyond abstract format but has been the subject of a commentary 249 
questioning the role of HIPEC [42,43]. Although the trialists must be commended on their work and 250 
efforts to evaluate the role of HIPEC, additional scrutiny of P7 has raised more questions. The 251 
unexpected benefit of CRS alone on median survival tests the validity of the number of patients in 252 
each arm, whilst the greater complication rate in the HIPEC arm (not seen in this series with a lower 253 
dose of oxaliplatin) may have influenced the median survival in that group. The authors have 254 
presented data (PSOGI Sept 2018 Paris) wherein for PCI < 15 there was a statistical difference in 255 
those receiving HIPEC. From the data available P7 demonstrates that CRS alone can be 256 
advantageous in CRPM whilst the additional role and appropriate dose of HIPEC requires further 257 
evaluation. Until so, this study provides valuable information for oncologists and patients regarding 258 
prognosis when peritoneal metastases are diagnosed and should encourage earlier referral and 259 
assessment regarding alternative treatments. 260 
 261 
5. Conclusions 262 
For CRPM patients who undergo CRS/HIPEC a low morbidity and mortality can be achieved and a 263 
survival benefit can be obtained. Increasing awareness of the potential benefits and low risks of 264 
CRS/HIPEC for CRPM should promote an increase in referrals. An experienced MDT should 265 
mentor new providers reducing the learning curve for selecting patients for potentially curative 266 
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Patients must  meet the following criteria: 
Peritoneal neoplasms (benign and malignant) of appendiceal or colorectal origin 
Disease distribution amenable to complete or near complete (residual individual tumours being no 
bigger than 2.5mm diameter – CC0 or CC1) surgical resection 
Absence of systemic disease at the time of referral i.e. could have been Dukes C treatment with 
adjuvant chemotherapy at initial presentation (nodal positivity, unresectable distant metastases) 
Performance status sufficient to withstand a major surgical procedure 
Availability of all previous relevant imaging, histology and medical notes 
Exclusion Criteria: 
Unresectable disease (>CC2) 
Significant co-morbidities 
Peritoneal carcinomatosis* of non-colorectal origin 
 
*Carcinomatosis is the term used by NHS England Commissioning although the preferred 
terminology is peritoneal metastasis 
Table(s)
 
Table 2: Published studies showing the survival advantage of CRS and HIPEC 
 
Table 2 
1st Author Year Study design N Key Findings (median OS in months) 
    CRS + HIPEC 
offered 





 2003 RCT 105 22.3 12.6 .032 
Glehen et al.
20
 * 2004 Retrospective  506 32.4 8.4 <.001 
Elias et al.
18
 2009 Retrospective  96 62.7 23.9 <.05 
Elias et al.
21
 * 2010 Retrospective  523 33 7 <.0001 
Cashin et al. 2016 RCT 48 25 18 .04 
Larentzakis et al. 2017 Prospective 
register 
286 46 13 N/A 
* EPIC was also used in a group of patients 
CRS: cytoreductive surgery, HIPEC: hyperthermic intraperitoneal chemotherapy, N: number of 





Temporal distribution of CRPM referrals per year. The study evaluated referrals from January 2002 
to June 2015 (*2015 half year only). 
 
Figure 2. 
CRS/HIPEC has not been offered, according to MDT recommendations. Percentages correspond to 
the 117 of 286 patients not receiving treatment. 
 
Figure 3. 
Temporal distribution of CRPM referrals per referral period, and the declining percentage of 
patients over the three referral periods. 
 
Figure 4. 
Overall survival of i) patients that received CRS/HIPEC (survival data were available for 114 of the 
117 patients), ii) patients that did not receive CRS/HIPEC at the Christie. iii) Overall survival from 
chemotherapy trials only, from the ARCAD consortium included for descriptive comparison[23]. 
No statistical testing performed as the treatment groups are no directly comparable. Time in months.  
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